C12N2795/10032

BACTERIA-TARGETING CAPSID PARTICLE, TREATMENT COMPOSITION, DISINFECTANT, FOOD, BACTERIA ELIMINATION METHOD, BACTERICIDAL METHOD, CORROSION PREVENTION METHOD, ANIMAL TREATMENT METHOD, GENE INTRODUCTION METHOD, BACTERIA FUNCTION ADDITION METHOD, METHOD FOR PRODUCING BACTERIA-TARGETING CAPSID PARTICLE, AND METHOD FOR PRODUCING NUCLEIC ACID FOR BACTERIA-TARGETING CAPSID PARTICLE
20250387442 · 2025-12-25 · ·

Provided is a bacteria-targeting capsid particle that is non-proliferative and has a high bactericidal effect. A capsid protein of a bacteriophage is prepared by a capsid nucleic acid element that synthesizes the capsid, which is divided from the bacteriophage genome and does not include a packaging region, but mainly includes the virion region. A bacteria-targeting capsid particle element (Bacteria-targeting capsid particle, B-CAP) is divided from a part of the bacteriophage genome other than the capsid nucleic acid element and includes a nucleic acid injection region, a replication region necessary for nucleic acid replication, and a packaging region. Although the assembled bacteria-targeting capsid particle (B-CAP) is non-proliferative, it can carry long DNA strands that give them new biological functions, such as bactericidal effects, or the other biological functions.

MYCOBACTERIOPHAGE COMPOSITIONS AND RELATED METHODS
20260108571 · 2026-04-23 · ·

Disclosed are isolated bacteriophages having lytic activity against a broad range of mycobacterial species, as well as phage cocktails comprising different mixtures of the isolated bacteriophages. The disclosed bacteriophages include Pill582, and variants thereof, having the ability to stimulate TLR2 signaling and limit intracellular bacterial survival within macrophages through the signalosome involving NLRP3 inflammasome activation leading to the caspase 1 activation and the production of pro-inflammatory cytokine IL-1. Also disclosed are compositions comprising the isolated bacteriophages or phage cocktails, including pharmaceutical compositions and compositions further comprising one or more non-phage therapeutic agents. The disclosed bacteriophage and phage cocktail compositions are useful in methods for treating mycobacterial infections and associated disease conditions.

STAPHYLOCOCCUS PHAGE COMPOSITIONS AND COCKTAILS THEREOF

Disclosed here are phage compositions for infecting and/or killing Staphylococcus spp.